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 Abstract  
Alpha-synuclein (α-syn) toxic aggregates delivered by the nasal vector have been shown to 
modify the neurochemistry of dopamine (DA) which is associated with parkinsonian-like motor 
symptoms. The aim was therefore to study the intranasal effects of α-syn oligomers, fibrils or their 
combination on the motor behavior of aged mice in relation to possible noradrenergic and 
serotonergic correlates. In vitro generated α-syn oligomers and fibrils were verified using atomic 
force microscopy and the thioflavin T binding assay. Levels of noradrenaline (NA), serotonin (5-
HT) and 5-hydroxyindoleacetic acid (5-HIAA) were detected using HPLC with electrochemical 
detection in the substantia nigra (SN) and striatum. The oligomers or fibrils administered alone or 
in a 50:50 combination (total dose of 0.48 mg/kg) were given intranasally for 14 days and “open-
field” behaviour was tested on days 0, 15 and 28 of the protocol, at which time brain structures 
were sampled. Behavioral deficits at the end of the 14-day dosing regime and on day 28 (i.e. 14 
days after treatment completion) induced hypokinesia and immobility whilst the aggregate 
combination additionally produced rigidity. The α-Syn oligomer/fibril mixture also instigated PD-
like motor symptoms which correlated heterochronically with elevated NA levels in the striatum 
but then later in the SN while intranasal fibrils alone augmented 5-HT and 5-HIAA nigral 
concentrations throughout the protocol. In contrast, α-syn oligomers displayed a delayed serotonin 
upsurge in the SN. Neurodegenerative and/or actions on neurotransmitter transporters (such as 
NET, SERT and VMAT2) are discussed as being implicated in these α-syn amyloid induced 
neurochemical and motoric disturbances. 
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1. Introduction 
Parkinson’s disease (PD) is a neurodegenerative disorder largely characterized by behavioural 
abnormalities which arise from aberrant brain neurochemistry [1]. PD motor signs (akinesia, 
rigidity, resting tremor and postural instability) have been ascribed primarily to progressive 
degeneration of dopaminergic neurons in the substantia nigra (SN) [2]. Current thinking suggests 
that neurotransmitters other than dopamine (DA) exhibit modulatory roles within the basal ganglia 
to directly and/or indirectly influence the dopaminergic system. Hence, various non-dopaminergic 
neurotransmitter systems have been implicated in the mechanisms which contribute to the motor 
features of PD. Accordingly, it is now well established that noradrenergic, serotonergic, 
glutamatergic, GABAergic, cholinergic, opioidergic, histaminergic, and adenosinergic systems, 
are implicated in the pathogenesis of PD [3]. Noradrenaline (NA), for example, is hypothesized to 
play a role in PD balance and gait dysfunction chiefly because of the disease-associated 
neurodegeneration connected with the locus coeruleus [4]. Similarly, it has been shown that the 
protein α-synuclein (α-syn) regulates the homeostasis not only of dopaminergic [5] and [6] but 
also serotonergic and noradrenergic synapses [7], [8] and [9] in addition to being a prion-like 
protein that can adopt a self-propagating conformation that causes neurodegeneration [10]. 
Moreover, α-syn can directly modulate the activity of monoamine transporters (MAT) including 
the dopamine transporter (DAT), serotonin transporter (SERT) and NET, leading to modified 
trafficking to the cell surface, in a manner that is dependent on α-syn expression levels [11], [12], 
[13], [14] and [15].  
Therefore, it has been established that PD involves a neuropathology in which α-syn and its 
amyloidogenic species, along with neurotransmitter systems (including DA, NA, serotonin (5-HT) 
and glutamate) are interrelated [16], [17] and [18]. In this respect, it is noteworthy that α-syn is co-
localized in terminals of noradrenergic (locus coeruleus) or serotonergic (raphe nuclei) neurons. α-
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Syn itself is known to be natively unstructured, but it is in equilibrium with subpopulations of 
more compact structures and it is these aggregates that are thought to be linked to amyloid 
formation [19], [20] and [21]. Both α-syn misfolding and intracellular aggregation processes are 
thought to be crucial factors in the pathogenesis of Lewy body PD [22], [23] and [24] but 
precisely how these phenomena are  linked to brain neurochemistry is still under debate. 
 In addition, the pathology of PD entails not only the loss of dopaminergic neurons in the SN but 
also degeneration of noradrenergic neurons in the locus coeruleus and deposition of misfolded α-
syn aggregates in Lewy bodies. α-Syn also modulates noradrenergic activity by its interaction with 
the NET via the non-Aβ component of Alzheimers disease amyloid (NAC) domain, the region 
directly responsible for self-aggregation [13]. Moreover, α-syn also regulates the function of 
serotonergic synapses, through trafficking of the serotonin transporter (SERT) [14]. The 
serotonergic system is also affected by the neurodegenerative process underlying PD and neuronal 
loss in the dorsal raphe nucleus leads to reduced serotonin levels in a variety of brain areas, 
including the striatum, globus pallidus, SN and some cortical areas [25] and [26]. Thus, α-syn has 
an important central role in the homeostasis of both serotonergic and noradrenergic neurons. 
 
In an earlier study, we instigated a novel PD model based on nasal inoculation with α-syn 
aggregates expressing parkinsonian-like behavioural and immunological features in mice [17]. 
More recently, we verified the robustness of the amyloid nasal vector model by examining 
behavioral consequences with respect to DA-ergic neurochemical corollaries [18]. Behavioral 
deficits at the end of a 14-day dosing regime and on day 28 (i.e. 14 days after treatment 
completion) induced rigidity, hypokinesia and immobility. This was accompanied by elevated 
nigral but not striatal DA, DOPAC and HVA concentrations in response to combined 
administration of α-syn oligomers plus fibrils but not the oligomers alone. α-Syn fibrils intensified 
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not only the hypokinesia and immobility 14 days post treatment, but also reduced vertical rearing 
and enhanced DA levels in the substantia nigra. Only nigral DA turnover (DOPAC/DA but not 
HVA/DA ratio) was augmented in response to fibril treatment but there were no changes in the 
striatum. Compilation of these novel behavioral and neurochemical findings substantiated the 
validity of the α-syn nasal vector model for investigating parkinsonian-like symptoms and this has 
prompted inquiry into the relationship between aberrant misfolded α-syn and other 
neurotransmitter systems with respect to PD-like motor activity. The aim of the current study was 
therefore to further validate the intranasal effects of α-syn oligomers, fibrils or their combination 
on the motor behavior of aged mice in relation to possible noradrenergic and serotonergic 
correlates.  
 
2. Materials and Methods 
Noradrenaline (NA) 5-hydroxytryptamine (serotonin, 5-HT) and 5-hydroxyindoleacetic acid (5-
HIAA) were obtained from Sigma, St. Louis, MO, USA. 
2.1. Subjects 
Adult male C57Bl/6 mice aged 12-months and weighing 31.1±1.0g were used throughout. The 
animals were group housed on a 12:12 light-dark cycle at a constant temperature of 21oC and 50% 
humidity with access to food and water ad libitum. All experimental procedures were carried out 
in accordance with the National Institute of Health Guide for the Care and Use of Laboratory 
Animals (NIH Publications No. 80-23, revised 1996); the UK Animals Scientific Procedures Act 
1986 and associated guidelines; the European Communities Council Directive of 24 November 
1986 (86/609/EEC) for care and use of laboratory animals. They were also approved by the 
Animal Care and Use Committee of the P.K. Anokhin Institute of Normal Physiology, Russian 
Academy of Medical Science. 
6 
 
2.2. Procedures and dosing protocol 
Experiments were performed between 10.00-15.00 hours and animals were divided into seven 
groups (n = 10 per group). Group (1; naïve control) was administered saline vehicle intranasally 
(i.n) bilaterally in a total volume of 8 µL/animal daily (i.e. 4 µL/nostril using a Hamilton syringe) 
over a total dosing period of 14-days. Group (2) was administered a solution of α-syn oligomeric 
aggregates (15.0 µg in 8 µL = 0.48 mg/kg) bilaterally using the same 14-day dosing schedule. 
Group (3) received α-syn fibrillar aggregates (15.0 µg in 8 µL = 0.48 mg/kg bilaterally) for the 14-
day schedule. Group (4) was co-administered aggregates of α-syn oligomers plus fibrils 
simultaneously each in a 50%:50% concentration of 7.5µg in 4 µL/animal bilaterally (i.e. total α-
syn equivalent dose 15 µg = 0.48 mg/kg) i.n. over the 14-day protocol. At the end of the 14-day 
protocol (i.e. on day 15), animal groups 1-4, underwent behavioural testing. They were then killed, 
both nigral as well as striatal neurochemical analysis subsequently being performed. The 14-day 
treatment schedule was also carried out for animal groups (5; oligomeric aggregates), (6; fibrillar 
aggregates) and (7; oligomers plus fibrils 50%:50%) then 14-days post treatment (i.e. day 28), 
they were tested behaviorally then killed and nigral along with striatal neurochemical analyses 
were completed. All behavioral tests and neurochemical analyses were performed under blind 
conditions. 
2.3. Behavioural tests 
Animal behavioural analysis was performed in all groups before (day 0), one day after the end of 
the α-syn amyloidogenic species dosing protocol (i.e. day 15), or 14 days post-treatment (i.e. day 
29) and a total of eight behavioural indicators of PD-mimetic symptoms (collectively assessing 
hypokinesia, muscle rigidity and tremor) were evaluated [27] and [28]. Firstly, hypokinesia was 
assessed by quantifying “open field” spontaneous locomotor activity based on previous 
methodologies but in response to MPTP treatment as a prototypic drug [29] and [30] for a period 
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of 0-6 min after 5 min acclimatization in an animal activity meter (Opto-Variomex-3 Auto-Track 
system, Columbus Instruments, Columbus, Ohio, USA). The 0-6 min recording time was chosen 
since it represented an optimal period for detecting neurotoxin-induced locomotor hypokinesia in 
3-minute intervals up to a total of 30 minutes in C57Bl/6 mice [27] and [31]. Additionally, total 
locomotor distance, cumulative ambulation time as well as speed (horizontal activity measures) 
and vertical rearing (vertical activity measure) as well as immobility time were recorded. 
Secondly, muscle rigidity was gauged using a “gibbosity” test manifested by the shortening of the 
neck to the tailbase measurement and scored by the following scoring scale: (0) = no rigidity; (1) 
= 1.0cm decrease; (2) = 2.0cm decrease; (3) = >2.0cm decrease [27]. Thirdly, the presence or 
absence of tremor was checked behaviourally [32] using the following scoring scale: (0) = no 
tremor; (1) = head tremor; (2) = head and forepaw tremor, (3) = whole body tremor.  
2.4. Production of α-synuclein  
Escherichia coli BL21 (DE3) cells transformed with pRK173 plasmid harbouring the α-synuclein 
gene were used for the production of the recombinant protein [33]. The recombinant protein was 
purified as previously described [34] with some modifications outlined below. Plated cultures 
were used to inoculate Nutrient Broth medium (Oxoid Ltd, UK) containing ampicillin. Cultures 
were grown until the late log-phase (A600 nm, 0.8) at 30°C and protein expression was induced with 
0.5 mM isopropyl-β-D-thiogalactopyranoside. The cells were cultured at 30°C overnight, 
harvested by centrifugation (3000 g, 20 min), washed, re-suspended in 50 mM Tris-HCl buffer, 
pH 7.5, containing 0.1 mM EDTA, 0.2 mM PMSF and disrupted by sonication. The cell 
homogenate was boiled for 10 min, the cell-free extract was loaded onto a HiPrep™ Q FF 16/10 
Column (GE Healthcare) in 20 mM Tris-HCl, pH 7.5, and eluted by a linear 0-1 M NaCl gradient. 
Fractions containing α-synuclein were analyzed by a Coomassie stained SDS-PAGE and dialized 
against 20 mM Tris, pH 7.5. Collected fractions were loaded onto a HiTrap ANX FF (high sub) 
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column and eluted by a linear 0-1 M NaCl gradient. Fractions containing α-synuclein were 
combined, dialized against 10 mM NH4HCO3 and lyophilized. 
 
2.5. Production of α-synuclein amyloidogenic species 
The α-syn  concentration  was  determined  by  optical  absorbance  measurements  at  280 nm  
(ND-1000  spectrophotometer, Nano-drop,  Sweden),  using  an  extinction  coefficient  E1 mg/ml= 
0.354 [35]. In order to produce amyloid oligomers and fibrils of α-synuclein, protein was 
incubated at 0.21 mM and 0.71 mM concentrations in 10 mM sodium phosphate buffer, pH 7.4 
and 37°C, using continuous agitation at 300 rpm during 7 and 14 days, respectively. The 
formation of oligomers and fibrils was verified as described earlier [27]. 
 2.6. Spectroscopic amyloid assays 
The thioflavin T (ThT) binding assay was performed using a modification of LeVine’s method 
[36]. Thioflavin T fluorescence was  measured  by  a  Jasco  FP-6500  spectrofluorometer  (Jasco, 
Japan),   using   excitation   at   440 nm   and   collecting   emission between  450–550 nm,  with  
excitation  and  emission  slits  set  at 3 nm width. Congo red assay was performed using a ND-
1000 spectrophotometer for optical absorbance measurements [35].  UV circular dichroism  (CD) 
measurements  were  carried out using  a Jasco  J-810  spectropolarimeter  (Jasco,  Tokyo,  Japan)  
equipped with a Jasco CDF-426L thermostat, employing  0.1- and 0.5-cm path length  cuvettes.  
At least three scans were averaged for each spectrum. 
 
2.7. Atomic force microscopy (AFM) 
AFM   measurements   were   performed   on   a   PICO   PLUS microscope   (Agilent,   USA)   in   
a   tapping   mode   as   outlined previously [37].  A  scanner  with  a  100 mm  scan  size  and 
acoustically driven cantilevers carrying etched silicon probes of the TESP model of 10 nm 
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diameter (Veeco, Netherlands) were used. Typically, we applied a resonance frequency in the 
312–340 kHz range,  scan  rate  of  1 Hz  and  a  resolution  of  5126512  pixels. Height, amplitude 
and phase data were collected simultaneously. Images were flattened and plane adjusted.  The  
scanning  of samples  was  performed  in  trace  and  retrace  to  avoid   scan artifacts. The scanner 
was calibrated by measuring atomic steps on highly  orientated  pyrolytic  graphite  in  the  z-axis  
and  using  a standard  1-mm  calibration  grid  (Agilent,  USA)  in  the  xy-plane. Amyloid 
samples were deposited on the surface of freshly cleaved mica  (Goodfellow,  UK)  for  30 min,  
washed  three  times  with 100 ml  of  MilliQ  water  and  dried  at  room  temperature.  To 
determine the dimensions of amyloid species cross-section analysis in the height images was 
carried out using PICO PLUS software (Agilent, USA). 
 
2.8. Neurochemical determination of tissue content of noradrenaline (NA), serotonin (5-HT) 
and it metabolite 5-hydroxyindole acetic acid in mouse brain structures by high performance 
liquid chromatography with electrochemical detection (HPLC/ED). 
 
Substantia nigra (SN) and striatum mouse brain structures (n=10 per group) were dissected on ice 
(+40C) then weighed and immediately stored in liquid nitrogen for subsequent analysis. Tissue 
samples were homogenized in 0.1 N perchloric acid (1:20) with 0.5 μM 3,4-dihydroxybenzoic 
acid as internal standard and centrifuged (10,000g x 10 min, 40C; Eppendorf 5415 R, Germany). 
The supernatant was analyzed by high performance liquid chromatography with electrochemical 
detection (HPLC/ED) [38]. NA, 5-HT and 5-HIAA were detected using a glassy carbon electrode 
set at +0.85 V compared with an Ag/AgCl reference electrode using an electrochemical detector 
LC-4B (Bioanalytical Systems, West Lafayette, Indiana, USA). The mobile phase contained 0.1 M 
citrate-phosphate buffer (pH 2.9), 1.85 mM 1-octanesulfonic acid, 0.27 mM ethylenediaminetetra-
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acetate (EDTA) and 8% acetonitrile and pH was adjusted to 3.0 with 6M KOH. All reagents used 
for the mobile phase were of analytical grade (Sigma-Aldrich, USA). The mobile phase was 
filtered through a 0.22 μm nylon filter (Merck Millipore, Merck KGaA, Germany). DA and its 
metabolites were separated by an analytical reverse-phase column on reprosil C18, pore size 4 μm, 
100 x 4 mm. (Dr. Maisch GMBH) at a flow rate of 1.0 ml/min. The experimental sample 
monoamine levels were quantified by external standard curve calibration using peak area for 
quantification. Sample analysis was performed using MULTICHROM 1.5 (Ampersand, Russia) 
software. Turnover of serotonin was expressed as the ratio of metabolite tissue concentration (5-
HIAA) to the parent monoamine (5-HT). Samples from all the animals were processed in parallel 
on the same day for each brain structure. Data were calculated as nM /g wet brain tissue. 
2.9. Statistical analysis 
Data were expressed as means ± s.e.m. Statistical analysis was performed using the Statistica 6 
package and homogeneity of variance was checked by Levene’s test. Since dispersion was not 
homogeneous within groups, non-parametric criteria were applied using the Mann-Whitney U-test 
for two populations and the Kruskal-Wallis test for multiple comparisons. Statistical significance 
was assumed at P < 0.05 for all measurements. 
 
 
 
     3. Results 
3.1. Characterisation of α-synuclein oligomeric and fibrillar aggregates  
Oligomeric species of α-synuclein were produced at pH 7.4 with agitation and characterized by 
the thioflavin-T binding assay. Then, AFM analysis was performed prior to intranasal 
administration, which was particularly important since amyloid species display an inherent 
diversity of structures dependent on solution conditions.  The samples containing α-synuclein 
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oligomers were collected at the end of the lag-phase (7 days), at which time a detectable 
fluorescence increase was observed, indicative of cross β-sheet formation. The oligomers and 
fibrils of α-syn also bind the amyloid specific dye - Congo red, which is reflected in a long-
wavelength shift and an increase of the dye absorbance spectra compared to the control 
measurement of the Congo red spectrum in the presence of monomeric α-syn. The generated 
oligomers of α-syn were characterized by a round-shaped morphology assessed by AFM imaging 
(Fig. 1A). The distribution of oligomeric particle heights measured in AFM cross-sections was 
carried out and they were represented by a wide range of species with heights from 1.2 nm to 3.9 
nm. Their maximal population was centered around species with ca. 1.8-2.0 nm heights, which 
corresponded to 20-mers as estimated previously and the oligomeric nature of these species has 
been verified by interaction with generic A11 antibodies reactive towards amyloid oligomers [27] 
and [39]. 
Mature fibrils were developed after 14 days of incubation and were characterized by a 10 fold 
increase in thioflavin-T fluorescence intensity which displayed typical fibrillar morphology with 
up to a micron length (Fig. 1B). They were constituted by a few single stranded protofilaments 
intertwined around each other and resulting in structures of 8 to 10 nm height measured by AFM 
cross-section analysis. In order to exclude the presence of some spontaneously formed fibrils in 
the oligomeric fractions, the oligomers produced at the lower concentration of protein (0.21 mM) 
were taken for further behavioural and neurochemical experiments. 
 
3.2. Behavioral analysis of PD-like activity on completion of 14-day intranasal dosing with α-
synuclein aggregates 
In pilot studies, the duration of sampling time following 5 min open field habituation for 
behavioural parameters was examined over three epochs, namely 0-3 min, 3-6 min and 0-6 min in 
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all animal groups before dosing, after dosing (i.e. day 15) and 14 days (i.e. day 29) after treatment 
completion. Statistical analysis showed no significant difference in behavioural parameter values 
(P>0.05) in any of the sampling times. Consequently, in order to capture the widest prospective 
behavioral profile, 0-6 minutes was selected for all behavioral study measurements.  
Animal behavioral analysis at the end of 14-day treatment with intranasal saline vehicle (control) 
revealed no significant change (P>0.05) in open field horizontal activity as reflected by mean total 
locomotor distance, cumulative ambulation time, ambulation speed, immobility time or vertical 
rearing behaviour. Neither was there any inherent evidence of muscle rigidity or tremor in any of 
these control vehicle-treated mice.  
 
3.2.1.  α-Synuclein oligomer treatment  
Similar to controls, there was no change (P>0.05) in any of the above behavioural parameters 
following 14-day i.n. treatment with α-syn oligomers (15µg/day i.e 0.48 mg/kg) nor any difference 
from corresponding control group values (Fig 2). In addition, there was no evidence of tremor or 
rigidity. 
 
3.2.2 .α-Synuclein fibril treatment  
In the α-syn fibril treatment group (Fig 2), there were significant reductions compared with 
controls (P<0.05) in total locomotor distance (77.5%), cumulative ambulation time (74.7%) and 
vertical rearing (70.3%) but an increase immobility time (123.75%, P<0.05) . 
 
3.2.3.  α-Synuclein oligomer and fibril combined treatment 
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Combined treatment with α-syn oligomers (7.5µg/day) plus fibrils (7.5µg/day) making a total 
equivalent dose of 15 µg/day (0.48 mg/kg) of α-syn species evoked a significant reduction in 
mean total locomotor distance traveled (P<0.001, Fig 2). When compared to the 14-day vehicle 
treatment control, this reduction was of a comparable magnitude (i.e. 76.7% of the after dosing 
control). Moreover, there was also a concomitant increase (P<0.05) in immobility time versus 
either the pre-dose value or the control (118.8%, Fig 2). Most notably, there was a presence of 
rigidity in animals which received the aggregate combination (P<0.001) and 70% of the group 
displayed Straub tail while the remaining 30% additionally manifested an arched back. 
In the case of ambulation speed, there were no significant differences between any of the mean 
group values for oligomer alone, oligomer plus fibril or fibril alone treatments throughout at the 
end of the 14-day treatment schedule (see Fig 2).  
 
3.3. Behavioral analysis of PD-like activity 14 days after treatment completion of intranasal 
dosing with α-synuclein aggregates  
An intervening post treatment washout period of fourteen days without treatment was chosen for 
the second behavioural session since it matched the initial 14 days of the treatment protocol. 
 
3.3.1. 14-days after treatment completion with α-synuclein oligomers  
Statistical analysis revealed significant differences (P<0.05) between the oligomer alone post 
treatment group and the vehicle post treatment controls with respect to decrements in total 
locomotor distance (59.1% of control), cumulative ambulation time (62.9%), and vertical rearing 
(45.3%) with a corresponding increase in  immobility time (128.3%, Fig 3) and no expression of 
tremor or rigidity.  
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3.3.2. 14-days after treatment completion with α-Synuclein oligomers plus fibrils 
Fourteen days after completion of combinative treatment with two species of α-syn aggregate 
there were changes in animal open field behaviour in comparison with the controls and those 
parameters which were tested before dosing. Thus, significant attenuations were observed versus 
control in total locomotor distance (46.6%, P<0.001), cumulative ambulation time (44.4%, 
P<0.05), vertical rearing (37.9%, P<0.05) and this was accompanied by an elevation of 
immobility time values (160.3%, P<0.05, Fig 3). 
Additionally, comparison of the 14-day post combination aggregate treatment completion group 
with their appropriate pre-dose groups disclosed an identical behavioral pattern of significant 
reductions in total locomotor distance (P<0.001), cumulative ambulation time (P<0.001), vertical 
rearing (P<0.001) accompanied by an elevation of immobility time values (P<0.001, Fig 3). 
 
3.3.3. 14-days after treatment completion with α-synuclein fibrils 
Fourteen days after completion of treatment with fibrillar α-syn aggregates, there were significant 
differences from the controls and those parameters which were tested before dosing. 
Consequently, significant decremental changes were exposed with respect to their controls for 
cumulative ambulation time (13.7%%, P<0.001) and vertical rearing (10.8%, P<0.001) which 
were accompanied by an elevation of immobility time values (207.8%, P<0.05, Fig 3). 
Likewise, comparison of the 14-day post fibrillar aggregate treatment completion group with the 
appropriate pre-dose group disclosed an analogous behavioral profile of significant reductions in 
total locomotor distance (P<0.001), cumulative ambulation time (P<0.001) and vertical rearing 
(P<0.001) which were accompanied by an elevation of immobility time values (P<0.001). 
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Regarding ambulation speed, there were no significant differences between any of the mean group 
values for oligomer alone, oligomer plus fibril or fibril alone 14-day post treatments throughout 
(see Fig 3) and there was no evidence of tremor or rigidity.  
 
3.4. Neurochemical assay of NA, 5-HT and 5-HIAA concentrations in the SN and striatum in 
control and α-synuclein aggregate treated mice. 
On completion of 14 days intranasal inoculation and also 14 days after treatment termination with 
different amyloidogenic species of α-syn, the levels of NA, 5-HT and 5-HIAA were measured in 
PD pathology relevant mice midbrain structures (SN and striatum). Control levels of NA on 
commencement of the protocol were 1.60±0.35 nM/g of wet tissue in the SN and 0.38±0.05 nM/g 
of wet tissue in the striatum. Control levels of 5-HT and 5-HIAA were respectively 7.62±2.71 
nM/g and 3.76±0.59 nM/g in the SN and 0.08±0.01 nM/g and 0.04±0.001 nM/g in the striatum. 
The control 5-HIAA/5-HT ratios at the start of the protocol were 0.49±0.21 in the SN and 
0.50±0.10 in the striatum.  
All NA, 5-HT and 5-HIAA levels following intranasal α-syn aggregate treatments were expressed 
as a percentage of these controls. 
 
3.4.1. NA concentrations in mouse SN after 14-day α-synuclein aggregate intranasal 
inoculation and 14 days after treatment cessation. 
After dosing with α-syn oligomers, there was no change in nigral NA levels (Fig 4A). In contrast, 
at the end of 14-day administration with α-syn fibrils, there was a significant increase (P<0.05) in 
NA concentration (2.96±0.04 nM/g of wet tissue, +81%) in the SN.  Furthermore, analysis of the 
16 
 
NA content after combinative treatment with the mixture of α-syn oligomeric/fibrillar species did 
not induce any change in nigral NA content.  
Fourteen days after cessation of treatment with a mixture of α-syn species exposed an 
augmentation (P<0.05) of the NA concentration to 10.2±1.5 nM/g of wet tissue, +537% (P<0.001) 
of control in the SN. However, no change occurred in the groups formerly treated with α-syn 
oligomers or fibrils (Fig 4B). 
 
3.4.2. NA concentrations in mouse striatum after 14-day α-synuclein aggregate intranasal 
inoculation and 14 days after treatment cessation. 
Scrutiny of NA striatal concentrations at the end of 14-day α-syn species treatment divulged no 
striking changes in levels compared with controls following oligomeric or fibrilar administration. 
Conversely, the aggregate combination treatment produced an extensive elevation (18.23±3.60 
nM/g of wet tissue, +4660%, P<0.001) of NA in the striatum (Fig 3A). A reversal of this effect 
back to the control levels was detected to the combination treatment along with no alterations in 
striatal NA to oligomers and fibrils given separately 14 days after protocol completion. (Fig 5A, 
B) 
 
3.4.3. 5-HT and 5-HIAA concentrations plus 5-HIAA/5-HT ratios in mouse SN after 14-day α-
synuclein aggregate intranasal inoculation and 14 days after treatment cessation. 
On completion of α-syn intranasal administration (14-days) there was no change in nigral 5-HT 
concentration following either oligomer or aggregate combinative (oligomer + fibril) treatment but 
(25.5±3.9 nM/g of wet tissue, i.e. +235.5 %, P<0.05) an increase in the level of this 
neurotransmitter after fibril alone exposure (Fig 6A). Simultaneously, the SN concentration of the 
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5-HT metabolite 5-HIAA was decreased (1.61±0.09 nM/g of wet tissue, -57.2%, P<0.05) by 
oligomer treatment, but increased (6.13±1.2 nM/g of wet tissue, +63%, P<0.05) after fibril 
administration while there was no change following the oligomer plus fibril combination. In 
addition, the 5-HIAA/5-HT ratio remained unchanged by any of the α-syn species 14-day 
treatments. 
Fourteen days after α-syn species treatment completion, 5-HT levels in the SN were elevated by 
oligomer alone dosing (16.1±2.99 nM/g of wet tissue, +111.81%, P<0.05) and fibril alone 
administration (12.6±2.0 nM/g of wet tissue, +65.7 %, P<0.05) but there was no change with the 
combinative species treated group (Fig 6B). However, there was a significant increase in the 5-
HIAA/5-HT ratio caused 14 days after the cessation of fibril treatment 0.75±0,15 +53 %, P<0.05, 
Fig 6B). 
 
3.5. 5-HT and 5-HIAA concentrations plus 5-HIAA/5-HT ratios in mouse striatum after 14-day 
α-synuclein aggregate intranasal inoculation and 14 days after treatment cessation. 
There were no significant alterations in 5-HT, 5-HIAA or 5-HIAA/5-HT ratios induced by 14-day 
i.n. treatment or 14 days after treatment cessation with α-synuclein oligomers, fibrils or their 
combination (Fig 7A, B). 
 
    4. Discussion 
Parkinson's disease is a degenerative condition of the central nervous system, whose 
neuropathology warrants further elucidation. The cardinal motor manifestations of PD which 
include rigidity, tremor and bradykinesia, are mostly regarded as the sequalae of a deficiency of 
dopamine in the SN and striatum [1] and [40]. Normal motor behavior involves the creation of 
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appropriate activity patterns across motor networks, enabling firing synchrony, synaptic 
integration, and normal functioning of these networks. The defective striatal signaling in PD could 
therefore lead to abnormal oscillatory activity and aberrant plasticity at multiple levels within the 
interlinked motor networks [41]. In the overall neuropathological symptom profile of PD, motor 
behavioural abnormalities are thought to originate not only from degeneration and loss of 
dopaminergic, but also noradrenergic and serotonergic neurons [26] and [42]. A considerable body 
of neuropathological, biochemical and genetic evidence suggests that the cerebral accumulation of 
amyloid fibrils is the core event in the pathogenesis of PD [43] and [44]. Oligomeric intermediates 
of α-syn are non-fibrillar polypeptide assemblies that occur during amyloid fibril formation and 
they are thought to underlie the aetiology of amyloid diseases, such as PD. Similar to the other 
amyloids [45], α-syn misfolding in the context of PD generates toxic amyloidogenic species [10] 
and [46] associated primarily with a perturbation of the DA system. In this connection, the 
carboxy terminal of the DA transporter (DAT) physically interacts with native α-syn [47] and it 
was subsequently shown that the α-syn NAC domain is implicated [11] and [12] (Fig 9). 
In a recent study, [18] we showed that α-syn aggregates delivered intranasally, induced changes in 
DA-ergic neurochemistry which correlated with motor deficits emphasizing the possibility that 
both toxic endogenous and exogenous substances [48] and [49] may cause neurodegenerative 
processes reflective of PD. Since DA and not its metabolites were affected by oligomeric α-syn, it 
has been suggested that in the initial stage of a DA-ergic system disbalance, the vesicular 
monoamine transporter (VMAT2) is a probable target for α-syn amyloid [18], (Fig 9). 
Furthermore, in the current protocol, the animals used were 12 months old and this is an important 
variable in an age-related model which is germane to the human neurodegenerative condition. 
Hence this particular model informs our knowledge concerning PD degeneration because it 
involves endogenous protein toxins (α-syn oligomeric and fibrillar amyloidogenic species) which 
are incited during the de facto disease process. [18]. The current data confirmed the alterations in 
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motor behavior, in the open-field mouse model after 14-days of intranasal inoculation with the α-
syn oligomer/fibril combination.  
These data therefore support the nasal vector hypothesis whereby introduced misfolded protein 
species penetrate brain structures changing structural functional interactions which then result in 
behavioral impairments. Such effects may persist beyond cessation of α-syn aggregate delivery 
[50]. 
In the striatum there was an extensive increase in NA levels on completion of treatment with the 
oligomer/fibril combination and this was associated with rigidity, hypokinesia and immobility. 
Along with elevated nigral DA [18] it appears that raised striatal NA also coincides with PD-like 
motor deficits. This may suggest that the NA terminals in this region were affected by α-syn 
aggregates thereby releasing their neurotransmitter. In relation to this tenet, it has been shown that 
an increasing level of α-syn expression in a cell model negatively modulates noradrenaline 
transporter (NET) reuptake by reducing the expression of this transporter at the neuronal cell 
surface [9], [13] and [15]. 
 
Intranasal delivery of the α-syn aggregate combination and conceivable access to the nigrostriatal 
area may change the normal interactions of α-syn with NET and also influence the expression of 
α-syn itself. An increasing level of α-syn expression negatively modulates NET uptake activity by 
decreasing NET expression at the cell surface [13] and [15]. Moderating NET function and 
changing membrane permeability will therefore perturb NA release and critically enhance its 
concentrations in the extracellular milieu. 
Fourteen days after cessation of treatment with the α-syn aggregate combination, the levels of 
striatal NA had returned to those of the controls and there was a delayed, but substantial, elevation 
of NA in the SN. This concurs with the hypothesis that aberrant α-syn toxic effects expressed in 
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the SN, preferentially degenerate NA terminals which are more vulnerable than the DA system 
and this accords with the major NA-ergic damage seen in PD patients [51]. 
The data emphasises the part played by the striatal α-syn amyloid disrupted NA-ergic system in 
tandem with dysregulated nigral DA function underlying PD motor deficits [18] (Fig 8). Thus, 
neurochemical heterochrony was operative since α-syn aggregates initially targeted DA cell 
bodies (SN) whilst simultaneously damaging striatal NA terminals. However, 14 days after 
cessation of aggregate treatment, nigral NA levels were boosted and DA concentrations were 
reduced but the motor deficits were maintained throughout.  
 
The toxic specificity of α-syn aggregates [46] was identified during analysis of their upshot on the 
serotonergic system which is known to be involved in PD pathogenesis [52]. It was interesting to 
note, that in the case of the serotonergic system, α-syn oligomers, fibrils or their combination did 
not evoke any effect in the striatum at the end of treatment or 14 days later. Hence, this protocol 
with aggregates of α-syn had no neurochemical activity with respect to serotonin or 5-HIAA in the 
striatum and this corresponds with previously reported results concerning striatal DA metabolism 
[18]. These findings are in sharp contrast with the NA augmentation seen currently at the end of 
dosing with the α-syn oligomer/fibril combination at which juncture marked rigidity was also 
present.    
A key brain area relevant to PD pathology (SN) expressed an upsurge in 5-HT concentrations at 
the end of α-syn fibril treatment and 14 days later. Both of these chronological phenomena were 
attended by mild bradykinesia and reduced rearing indicating that there may be a causal link. It is 
notable that native α-syn physically and functionally interacts with the serotonin transporter 
(SERT) in a negative modulatory fashion which is NAC dependent [14]. Thus, brain regional 
dispersion of α-syn fibrillar aggregates changes the functional interactions of native α-syn not only 
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regarding NET but also SERT and this is reflected by the monoamine neurochemistry presently 
observed (Figs 8 and 9).  
In addition, raised levels of 5-HIAA in the SN following fibrillar treatment and after treatment 
washout support the notion that 5-HT release is markedly increased from nigral serotonergic 
terminals. Moreover, the lagged fibril-induced raised ratio of 5-HIAA/5-HT was further evidence 
of an increase in 5-HT release in this brain area. In the light of this, in the oligomeric post-
treatment period, the concentration of 5-HT was augmented. This finding demonstrates the 
delayed toxic effects of α-syn oligomers on serotonergic terminals as a source of 5-HT release 
which was associated with motor poverty (Fig 8). Surprisingly, using the current protocol, there 
was no effect of combinative oligomer plus fibril treatment on the nigral serotonin concentration 
which could be attributed to an insufficient fibril concentration in the mixture. The central event 
leading to synaptic and neuronal loss in PD is not completely clear yet. However, recent advances 
in the field suggest that nerve damage might chiefly result from the conversion of nontoxic 
monomers to toxic oligomers and protofibrils. The mechanisms by which misfolded α-syn species 
may lead to synapse loss are currently under investigation. In the case of intranasally administered 
misfolded α-syn aggregates, there are inevitable differences from native α-syn regarding their 
interactions with the above processes. α-Syn amyloidogenic species may contribute by increasing 
soluble α-syn in the extracellular space thereby seeding additional aggregation [23], [53] and [54]. 
Moreover, a contemporary view posits that oligomeric α-syn is the misfolded form of the protein 
most likely to cause neuronal death [55]. Several lines of evidence support the possibility that α-
syn might interact to cause mitochondrial and plasma membrane damage upon translocation of its 
protofibrils to the membranes [56]. However the possibility cannot be excluded that α-syn 
aggregates may directly disrupt cell membranes or vesicles via initiation of amyloid apoptotic 
pores [57] and [58] (Fig 9) and initiate an apoptotic cascade leading to cell death [59].  Finally, 
there is increasing evidence that  α-syn binds to various cellular proteins, for instance, p-21-
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activated kinase 4 (PAK4) and because of this property, toxic α-syn oligomers may affect 
physiological function, [60]. Signaling deficits arising from such a mechanism may therefore be a 
notable contributory element in the behavioral defects in PD. 
In summary, nasal inoculation with different types of α-syn amyloidogenic species instigated PD-
like motor symptoms which correlated not only with DA [18] but also NA and serotonin 
disordered neurochemistry. These findings substantiate the involvement NA and serotonin 
pathways in α-syn amyloid intervention in motor function. A distinct possibility is that α-syn 
aggregates interact with monoamine transporters (Fig 9) in mediating the deviant motor behavior.  
Novel data concerning α-syn amyloid intervention in monoaminergic transmission provides an 
insight into future possibilities for PD therapy targeting not only DA-ergic but also NA-ergic and 
serotonergic systems. 
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Figure legends 
Fig. 1. Characterisation of generated α-synuclein amyloidogenic species 
Atomic force microscopy (AFM) images of generated α-synuclein amyloid species produced in 
sodium phosphate buffer pH 7.4 at 22oC with agitation.  
(A) AFM height images of amyloid oligomers formed after 7 days of incubation (scale bar = 180 
nm);  
(B) AFM height images of amyloid fibrils of α-synuclein produced under the same conditions 
after 14 days of incubation (scale bar = 800 nm).   
 
Fig. 2. Behavioral parameters recorded for 0-6 mins at the end of 14-day intranasal daily 
dosing with α-synuclein aggregates. 
Behavioral components including total locomotor distance, cumulative ambulation time, 
immobility time, ambulation speed, vertical rearing and rigidity were recorded before and at the 
end of the dosing schedule (after dosing). During the schedule, groups of mice were treated daily 
for 14 days with: α-synuclein oligomeric (7.5µg) plus fibrillar (7.5µg) aggregates, α-synuclein 
oligomeric aggregates (15µg) or α-synuclein fibrillar aggregates (15µg) and the data are presented 
as radar plots. In the case of the combined oligomer plus fibril treated group the rigidity score is 
shown in the highlighted star. 
*P<0.05; ** P<0.001 for the after dosing groups in comparison with their chronologically 
simultaneous controls. 
 
Fig. 3. Behavioral parameters recorded for 0-6 mins 14 days after treatment completion with 
daily intranasal α-synuclein aggregates. 
Behavioral components including total locomotor distance, cumulative ambulation time, 
immobility time, ambulation speed, vertical rearing and rigidity were recorded before and 14 days 
after the dosing schedule. During the schedule, groups of mice were treated daily for 14 days with: 
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α-synuclein oligomeric (7.5µg) plus fibrillar (7.5µg) aggregates, α-synuclein oligomeric 
aggregates (15µg) or α-synuclein fibrillar aggregates (15µg) and the data are presented as radar 
plots. 
*P<0.05; ** P<0.001 for the groups 14 days after treatment completion (after dosing) in 
comparison with their chronologically simultaneous controls. 
 
Fig. 4. NA content in mouse substantia nigra (SN) following 14-day treatment or 14 days 
after the treatment completion with amyloidogenic α-synuclein species either alone or in 
combination.  
All values (mean ± sem, n = 10 per group) were expressed as % of the following nigral control 
concentration: NA = 1.60± 0.35 nM/g of tissue. 
 (A) NA content in SN (% control) at the end of 14-day treatment with α-syn oligomers (black 
bars), α-syn fibrils (grey bars) or α-syn oligomers + α-syn fibrils (open bars). 
 (B) NA content in SN (% control) 14 days after the treatment completion with α-syn oligomers 
(black bars), α-syn fibrils (grey bars) or α-syn oligomers + α-syn fibrils (open bars). 
*P<0.05, in comparison with control, α-syn oligomers or α-syn oligomers + α-syn fibril treatment 
; ** P<0.001 in comparison with control, α-syn oligomers, or single α-syn fibrillar treatment.  
 
Fig. 5. NA content in mouse striatum following 14-day treatment or 14 days after the 
treatment completion with amyloidogenic α-synuclein species either alone or in combination.  
All values (mean ± sem, n = 10 per group) were expressed as % of the following striatal control 
concentration: NA = 0.38±0.05 nM/g of tissue. 
(A) NA content in striatum (% control) at the end of 14-day treatment with α-syn oligomers (black 
bars), α-syn fibrils (grey bars) or α-syn oligomers + α-syn fibrils (open bars). 
(B) NA content in striatum (% control) 14 days after the treatment completion with α-syn 
oligomers (black bars), α-syn fibrils (grey bars) or α-syn oligomers + α-syn fibrils (open bars). 
** P<0.01 in comparison with control and α-syn oligomer or α-syn fibrilar treatments alone.  
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Fig. 6. 5-HT and 5-HIAA content as well as the 5-HT/5-HIAA ratio in mouse substantia 
nigra (SN) following 14-day treatment or 14 days after the treatment completion with 
amyloidogenic α-synuclein species either alone or in combination.  
All values (mean ± sem, n = 10 per group) were expressed as % of the following nigral control 
concentrations: 5-HT = 7.62±2.11 nmol/g tissue, 5-HIAA = 3.76±0.59 nM/g  tissue or the 5-HT/5-
HIAA control ratio = 0.49±0.21 nmol/g tissue. 
(A) 5-HT (black bars) and 5-HIAA (grey bars) content or the 5-HIAA/5-HT ratio (open bars) in 
the SN (% control) at the end of 14-day treatment with α-syn oligomers , α-syn fibrils or α-syn 
oligomers + α-syn fibrils. 
(B) 5-HT (black bars) and 5-HIAA (grey bars) content or the 5-HIAA/5-HT ratio (open bars) in 
the SN (% control) 14 days after the treatment completion with α-syn oligomers , α-syn fibrils or 
α-syn oligomers + α-syn fibrils. 
*P<0.05, in comparison with control 5-HT, 5-HIAA nigral concentrations or the 5-HIAA/5-HT 
ratio  
 
Fig. 7. 5-HT and 5-HIAA content as well as the 5-HT/5-HIAA ratio in mouse striatum 
following 14-day treatment or 14 days after the treatment completion with amyloidogenic α-
synuclein species either alone or in combination.  
All values (mean ± sem, n = 10 per group) were expressed as % of the following striatal control 
concentrations: 5-HT = 0.08±0.01 nM/g tissue and 5-HIAA = 0.04±0.001 nM/g tissue nmol/g 
tissue or the 5-HT/5-HIAA control ratio = 0.50±0.10 nM/g tissue. 
(A) 5-HT (black bars) and 5-HIAA (grey bars) content or the 5-HIAA/5-HT ratio in the striatum 
(% control) at the end of 14-day treatment with α-syn oligomers, α-syn fibrils or α-syn oligomers 
+ α-syn fibrils. 
(B) 5-HT (black bars) and 5-HIAA (grey bars) content or the 5-HIAA/5-HT ratio in the striatum 
(% control) 14 days after the treatment completion with α-syn oligomers, α-syn fibrils or α-syn 
oligomers + α-syn fibrils. 
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Fig. 8. Scheme providing an overview of behavioural and neurochemical outcomes (striatal 
or nigral NA, 5-HT and 5-HIAA levels or 5-HIAA/5-HT ratios) at the end of 14-day 
treatment or 14 days after the treatment completion with α-synuclein oligomers, fibrils or 
oligomers plus fibrils. 
 
Fig. 9.  Prospective α-synuclein aggregate (oligomer and fibril) influence on monoamine 
homeostasis and transporter trafficking in central neuronal terminals. 
Generated wild-type α-Synuclein (α-syn) oligomers and fibrils have been proposed (1) to mix and 
seed aggregates inter- and intra-neuronally [23] and [54]. Once located intracellularly, (1a) the 
oligomers may (1b) propagate fibrils and have the potential (2) to influence monoamine 
biosynthesis by modifying/overactivating not only tyrosine hydroxylase, the rate limiting enzyme in 
catecholamine (DA and NA) synthesis [61], but also aromatic amino acid decarboxylase activity in 
dopaminergic cells [62]. In this regard, a loss of neuronal nuclei containing tryptophan hydroxylase, 
the rate limiting serotonin synthesizing enzyme, has also been associated with neurodegenerative 
synucleinopathies [63]. (3) There is evidence that native α-syn is implicated in the storage and 
release of monoaminergic transmitters via loading [9] and refilling of vesicles [64] and [65], 
vesicular monoamine transporter 2 (VMAT2) expression [66] as well as vesicular distribution and 
translocation [13] and [67]. Consequently, these monoamine vesicular mechanisms are inevitably 
modified by the formation of α-syn misfolded species with an ensuing impact on monoamine 
function. Similarly, native α-syn also (4) modulates monoamine neuronal reuptake by means of the 
monoamine transporters (MAT) which include DAT [68], NET [15] and [69] and SERT [14] so α-
syn aggregation will also impinge on presynaptic monoamine resorption processes. (5) Finally, α-
syn oligomers have been shown to evoke inappropriate permeabilisation of cell membranes [57] and 
amyloid pore formation [54] and [70] and these actions are detrimental to neuronal integrity and 
overall survival. 
